Soleus Capital Management
Latest statistics and disclosures from Soleus Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TEVA, UTHR, GSK, Rayzebio, EDAP, and represent 27.17% of Soleus Capital Management's stock portfolio.
- Added to shares of these 10 stocks: HCA (+$28M), IDYA (+$20M), PEN (+$20M), Rayzebio (+$18M), GSK (+$12M), NUVL (+$12M), TMDX (+$9.7M), Harpoon Therapeutics (+$9.3M), SNDX (+$8.5M), RVMD (+$7.2M).
- Started 16 new stock positions in ILMN, Harpoon Therapeutics, IDYA, RVMD, PEN, TMDX, DNLI, VYNE, Adverum Biotechnologies, SILK. HCA, ImmunoGen, PTGX, HOLX, ABBV, VRDN.
- Reduced shares in these 10 stocks: , TGTX (-$38M), ACLX (-$27M), , INBX (-$20M), EOLS (-$19M), CRL (-$19M), SRDX (-$17M), AXSM (-$17M), ORGO (-$14M).
- Sold out of its positions in AADI, ACAD, ALNY, ALPN, AVDL, AXSM, BHC, BLFS, BNTX, CRL.
- Soleus Capital Management was a net seller of stock by $-339M.
- Soleus Capital Management has $901M in assets under management (AUM), dropping by -16.85%.
- Central Index Key (CIK): 0001802630
Tip: Access up to 7 years of quarterly data
Positions held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Soleus Capital Management
Soleus Capital Management holds 73 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 6.4 | $58M | -8% | 5.6M | 10.44 |
|
| United Therapeutics Corporation (UTHR) | 6.1 | $55M | -13% | 249k | 219.89 |
|
| GSK Sponsored Adr (GSK) | 5.3 | $47M | +35% | 1.3M | 37.06 |
|
| Rayzebio | 5.2 | $46M | +65% | 747k | 62.17 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 4.2 | $38M | +15% | 7.2M | 5.28 |
|
| Organogenesis Hldgs (ORGO) | 4.1 | $37M | -27% | 9.0M | 4.09 |
|
| Humana (HUM) | 3.7 | $34M | +7% | 74k | 457.81 |
|
| Celcuity (CELC) | 3.5 | $32M | +5% | 2.2M | 14.57 |
|
| Iradimed (IRMD) | 3.4 | $31M | +2% | 643k | 47.47 |
|
| Essa Pharma Com New (EPIX) | 3.2 | $29M | 4.3M | 6.60 |
|
|
| SurModics (SRDX) | 3.1 | $28M | -37% | 772k | 36.35 |
|
| Hca Holdings (HCA) | 3.0 | $28M | NEW | 102k | 270.68 |
|
| Vaxcyte (PCVX) | 2.9 | $26M | -16% | 416k | 62.80 |
|
| Neuropace (NPCE) | 2.8 | $25M | 2.4M | 10.31 |
|
|
| Nuvalent Inc-a (NUVL) | 2.6 | $24M | +109% | 323k | 73.59 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 2.5 | $23M | 9.8M | 2.31 |
|
|
| Ideaya Biosciences (IDYA) | 2.2 | $20M | NEW | 565k | 35.58 |
|
| Penumbra (PEN) | 2.2 | $20M | NEW | 79k | 251.54 |
|
| Axogen (AXGN) | 2.0 | $18M | -31% | 2.6M | 6.83 |
|
| AtriCure (ATRC) | 1.6 | $14M | +28% | 392k | 35.69 |
|
| Rigel Pharmaceuticals Com New (RIGL) | 1.5 | $14M | -36% | 9.4M | 1.45 |
|
| Immunovant (IMVT) | 1.5 | $13M | -20% | 317k | 42.13 |
|
| Treace Med Concepts (TMCI) | 1.4 | $13M | -46% | 1.0M | 12.75 |
|
| Smith & Nephew Spdn Adr New (SNN) | 1.4 | $13M | -28% | 470k | 27.28 |
|
| Verastem Com New (VSTM) | 1.3 | $12M | +5% | 1.4M | 8.14 |
|
| Syndax Pharmaceuticals (SNDX) | 1.2 | $11M | +330% | 514k | 21.61 |
|
| Tg Therapeutics (TGTX) | 1.2 | $11M | -77% | 650k | 17.08 |
|
| C4 Therapeutics Com Stk (CCCC) | 1.2 | $10M | -31% | 1.8M | 5.65 |
|
| Bioatla (BCAB) | 1.1 | $10M | -6% | 4.1M | 2.46 |
|
| Transmedics Group (TMDX) | 1.1 | $9.7M | NEW | 123k | 78.93 |
|
| Harpoon Therapeutics Com New | 1.0 | $9.3M | NEW | 821k | 11.37 |
|
| Arcellx Common Stock (ACLX) | 1.0 | $8.8M | -75% | 159k | 55.50 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.9 | $8.4M | 965k | 8.75 |
|
|
| Tango Therapeutics (TNGX) | 0.9 | $8.4M | -56% | 847k | 9.90 |
|
| Merus N V (MRUS) | 0.9 | $8.3M | -21% | 303k | 27.50 |
|
| Viking Therapeutics (VKTX) | 0.9 | $8.1M | +256% | 436k | 18.61 |
|
| Jasper Therapeutics | 0.9 | $7.8M | +18% | 9.9M | 0.79 |
|
| Theratechnologies Com New (THTX) | 0.9 | $7.8M | +105% | 4.8M | 1.62 |
|
| Revolution Medicines (RVMD) | 0.8 | $7.2M | NEW | 252k | 28.68 |
|
| Si-bone (SIBN) | 0.8 | $7.2M | -46% | 342k | 20.99 |
|
| Silk Road Medical Inc Common (SILK) | 0.7 | $6.6M | NEW | 537k | 12.27 |
|
| Pharvaris N V (PHVS) | 0.7 | $6.1M | -36% | 217k | 28.05 |
|
| Insmed Com Par $.01 (INSM) | 0.6 | $5.2M | -23% | 167k | 30.99 |
|
| Krystal Biotech (KRYS) | 0.6 | $5.0M | -66% | 40k | 124.06 |
|
| CVS Caremark Corporation (CVS) | 0.5 | $4.7M | -69% | 60k | 78.96 |
|
| Iovance Biotherapeutics (IOVA) | 0.5 | $4.5M | -55% | 555k | 8.13 |
|
| Novocure Ord Shs (NVCR) | 0.5 | $4.5M | -12% | 301k | 14.93 |
|
| Inspiremd (NSPR) | 0.4 | $3.9M | 1.4M | 2.81 |
|
|
| Miragen Therapeutics (VRDN) | 0.3 | $3.0M | NEW | 138k | 21.78 |
|
| Denali Therapeutics (DNLI) | 0.3 | $2.8M | NEW | 130k | 21.46 |
|
| Xenon Pharmaceuticals (XENE) | 0.3 | $2.7M | +11% | 58k | 46.06 |
|
| Hologic (HOLX) | 0.3 | $2.4M | NEW | 34k | 71.45 |
|
| Annexon (ANNX) | 0.3 | $2.3M | 515k | 4.54 |
|
|
| Abbvie (ABBV) | 0.3 | $2.3M | NEW | 15k | 154.97 |
|
| Protagonist Therapeutics (PTGX) | 0.2 | $1.9M | NEW | 83k | 22.93 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.2 | $1.7M | -75% | 95k | 18.08 |
|
| Vyne Therapeutics (VYNE) | 0.2 | $1.6M | NEW | 704k | 2.33 |
|
| Applied Therapeutics (APLT) | 0.2 | $1.5M | -61% | 461k | 3.35 |
|
| Nurix Therapeutics (NRIX) | 0.2 | $1.5M | -82% | 143k | 10.32 |
|
| Y Mabs Therapeutics (YMAB) | 0.1 | $1.1M | 157k | 6.82 |
|
|
| Avita Therapeutics (RCEL) | 0.1 | $1.0M | 75k | 13.72 |
|
|
| Apogee Therapeutics (APGE) | 0.1 | $978k | 35k | 27.94 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 0.1 | $927k | -63% | 46k | 20.26 |
|
| Illumina (ILMN) | 0.1 | $738k | NEW | 5.3k | 139.24 |
|
| Inhibrx (INBX) | 0.1 | $570k | -97% | 15k | 38.00 |
|
| Castle Biosciences (CSTL) | 0.1 | $561k | -90% | 26k | 21.58 |
|
| The Beauty Health Company Com Cl A (SKIN) | 0.1 | $482k | -94% | 155k | 3.11 |
|
| Immunic (IMUX) | 0.0 | $450k | 300k | 1.50 |
|
|
| ImmunoGen | 0.0 | $387k | NEW | 13k | 29.65 |
|
| Adverum Biotechnologies | 0.0 | $320k | NEW | 425k | 0.75 |
|
| Genedx Holdings Corp Com Cl A (WGS) | 0.0 | $165k | -92% | 60k | 2.75 |
|
| Xeris Pharmaceuticals (XERS) | 0.0 | $146k | -79% | 62k | 2.35 |
|
| Liquidia Corporation Com New (LQDA) | 0.0 | $120k | -94% | 10k | 12.03 |
|
Past Filings by Soleus Capital Management
SEC 13F filings are viewable for Soleus Capital Management going back to 2019
- Soleus Capital Management 2023 Q4 filed Feb. 14, 2024
- Soleus Capital Management 2023 Q3 filed Nov. 14, 2023
- Soleus Capital Management 2023 Q2 filed Aug. 14, 2023
- Soleus Capital Management 2023 Q1 filed May 15, 2023
- Soleus Capital Management 2022 Q4 filed Feb. 14, 2023
- Soleus Capital Management 2022 Q3 filed Nov. 14, 2022
- Soleus Capital Management 2022 Q2 filed Aug. 15, 2022
- Soleus Capital Management 2022 Q1 filed May 16, 2022
- Soleus Capital Management 2021 Q4 filed Feb. 14, 2022
- Soleus Capital Management 2021 Q3 filed Nov. 15, 2021
- Soleus Capital Management 2021 Q2 filed Aug. 16, 2021
- Soleus Capital Management 2021 Q1 filed May 17, 2021
- Soleus Capital Management 2020 Q4 restated filed April 29, 2021
- Soleus Capital Management 2020 Q4 filed Feb. 16, 2021
- Soleus Capital Management 2020 Q3 filed Nov. 13, 2020
- Soleus Capital Management 2020 Q2 filed Aug. 14, 2020